J Breast Cancer.  2006 Jun;9(2):91-97. 10.4048/jbc.2006.9.2.91.

Up-regulation of P13K/Akt Signaling by 17 beta-estradiol through Activation of Estrogen Receptor-alpha in Breast Cancer Cells

• So MC
• Hwang HP
• Lee CH
• Youn HJ
• Jung SH
• Kim JC

• KMID: 2286625
• DOI: http://doi.org/10.4048/jbc.2006.9.2.91

Abstract

PURPOSE
Estrogen stimulates cell proliferation in breast cancer, the biological effects of which are mediated through two intracellular receptors: estrogen receptor-alpha (ERalpha) and estrogen receptor-beta (ERbeta). However, the actual role of ERs in the proliferative action of estrogen remains to be established. It was recently found that ER activates phosphatidylinositol-3-OH kinase (PI3K), via its binding with the p85 regulatory subunit of PI3K. Therefore, possible mechanisms may include ER-mediated phosphoinositide metabolism, with the subsequent formation of phosphatidylinositol-3, 4, 5-trisphosphate (PIP(3)), which is generated from phosphatidylinositol 4, 5-bisphosphate (PIP(2)) via PI3K activation. The present study has demonstrated that 17b-estradiol (E2) up-regulates PI3K in an ERalpha, but not an ERbeta dependent manner, and also stimulates cell growth in breast cancer cells.
METHODS
To study this phenomenon, we treated ER-positive MCF-7 cells and ER-negative MDA-MB-231 cells with 10 nM E2.
RESULTS
The treatment of MCF-7 cells with E2 resulted in a marked increase in the expression of PI3K (p85), which was paralleled by increases in the levels of phospho-Akt (Ser-473) and PIP3. These observations were also correlated with increased E2-induced cell proliferation activity. However, no effects of E2 on breast cancer cells were observed in the MDA-MB-231 cell line, indicating the pathway of E2-mediated up-regulation of PI3K/Akt is ERalpha-dependent.
CONCLUSION
These results suggest that estrogen activates PI3K/Akt signaling via an ERalpha-dependent mechanism in MCF-7 cells.

Keyword

Estrogen receptor; PI3K; PIP(3); 17beta-estradiol

MeSH Terms

Breast Neoplasms*
Breast*
Cell Line
Cell Proliferation
Estradiol*
Estrogen Receptor alpha
Estrogen Receptor beta
Estrogens*
MCF-7 Cells
Metabolism
Phosphatidylinositol 3-Kinases
Phosphatidylinositols
Up-Regulation*
Estradiol
Estrogen Receptor alpha
Estrogen Receptor beta
Estrogens
Phosphatidylinositol 3-Kinases
Phosphatidylinositols

Reference

1. Rose PG. Endometrial carcinoma. N Engl J Med. 1996. 335:640–649.

2. Clemons M, Goss P. Estrogen and the risk of breast cancer. N Engl J Med. 2001. 344:276–285.

3. Ikeda K, Inoue S. Estrogen receptors and their downstream targets in cancer. Arch Histol Cytol. 2004. 67:435–442.

4. Ray G, Banerjee S, Saxena NK, Campbell DR, Van Veldhuizen P, Banerjee SK. Stimulation of MCF-7 tumor progression in athymic nude mice by 17beta-estradiol induces WISP-2/CCN5 expression in xenografts: a novel signaling molecule in hormonal carcinogenesis. Oncol Rep. 2005. 13:445–448.

5. Simoncini T, Hafezi-Moghadam A, Brazil DP, Ley K, Chin WW, Liao JK. Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature. 2000. 407:538–541.

6. Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S, Nakshatri H. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J Biol Chem. 2001. 276:9817–9824.

7. Rameh LE, Cantley LC. The role of phosphoinositide 3-kinase lipid products in cell function. J Biol Chem. 1999. 274:8347–8350.

8. Osaki M, Oshimura M, Ito H. PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis. 2004. 9:667–676.

9. Wymann MP, Marone R. Phosphoinositide 3-kinase in disease: timing, location, and scaffolding. Curr Opin Cell Biol. 2005. 17:141–149.

10. Whitman M, Downes CP, Keeler M, Keller T, Cantley L. Type I phosphatidylinositol kinase makes a novel inositol phospholipid, phosphatidylinositol-3-phosphate. Nature. 1988. 332:644. 646.

11. Tolias KF, Cantley LC. Pathways for phosphoinositide synthesis. Chem Phys Lipid. 1999. 98:69–77.

12. Vanhaesebroeck B, Leevers SJ, Ahmadi K, Timms J, Katso R, Driscoll PC, et al. Synthesis and function of 3-phosphorylated inositol lipids. Annu Rev Biochem. 2001. 70:535–602.

13. Coffer PJ, Jin J, Woodgett JR. Protein kinase B (c-Akt): a multifunctional mediator of phosphatidylinositol 3-kinase activation. Biochem J. 1998. 335:1–13.

14. Oudit GY, Sun H, Kerfant BG, Crackower MA, Penninger JM, Backx PH. The role of phosphoinositide-3 kinase and PTEN in cardiovascular physiology and disease. J Mol Cell Card. 2004. 37:449–471.

15. Niswender KD, Gallis B, Blevins JE, Corson MA, Schwartz MW, Baskin DG. Immunocytochemical detection of phosphatidylinositol 3-kinase activation by insulin and leptin. J Histochem Cytochem. 2003. 51:275–283.

16. Nephew KP, Ray S, Hlaing M, Ahluwalia A, Wu SD, Long X, et al. Expression of estrogen receptor coactivators in the rat uterus. Biol Reprod. 2000. 63:361–367.

17. Carpenter CL, Cantley LC. Phosphoinositide kinases. Biochemistry. 1990. 29:11147–11156.

18. Stambolic V, Suzuki A, De la Pompa JL, Brothers GM, Mirtsos C, Sasaki T, et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell. 1998. 95:29–39.

19. Kim JS, Peng X, De PK, Geahlen RL, Durden DL. PTEN controls immunoreceptor (immunoreceptor tyrosine-based activation motif) signaling and the activation of Rac. Blood. 2002. 99:694–697.

20. Maehama T, Dixon JE. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem. 1998. 273:13375–13378.

21. Myers MP, Pass I, Batty IH, Van der Kaay J, Stolarov JP, Hemmings BA, et al. The lipid phosphatase activity of PTEN is critical for its tumor suppressor function. Proc Natl Acad Sci U S A. 1998. 95:13513–13518.

22. Tonks NK, Myers MP. Structural assets of a tumor suppressor. Science. 1999. 286:2096–2097.

23. Nicholson KM, Anderson NG. The Akt/PKB signaling pathway in human malignancy. Cell Signal. 2002. 14:381–395.

24. Song G, Ouyang G, Bao S. The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med. 2005. 9:59–71.